Dr. Robert Epstein is a physician epidemiologist with an interest in accelerating the adoption of true innovations of novel healthcare solutions.
For the past seven years, he has been the CEO and co-founder of Epstein Health LLC, a strategic consulting company servicing the private equity, healthcare and life science industries. Key topics in these engagements revolve around the application of digital solutions to research and/or healthcare, incorporation of genomics into the ecosystem, and the role of Real World Evidence in driving regulatory and/or commercial decisions.
He most recently left a 17-year post as Chief Medical and Chief R&D Officer for Medco (a 65 million life publicly traded PBM), where he managed a global department of over 2000 researchers in 33 offices (UBC) servicing the Life Sciences Industry, and provided information and services to more than 2000 US payers. While there, he initiated a series of innovative Personalized Medicine initiatives that branded Medco the #3 Most Innovative Company by Fortune Magazine (behind Apple and Nike).
Prior to Medco, Dr. Epstein was VP of Outcomes Research at Merck and had an earlier career in public health and academia focused on data mining to address epidemiologic questions. He has published more than 100 research papers in the peer-reviewed medical literature, and is currently tracking and engaging with developers of hundreds of new technologies. He currently serves on the Boards of Directors of Illumina (ILMN), Fate (FATE) Therapeutics, Veracyte (VCYT), and Proteus Digital Health.
He is Past President of ISPOR and has been a member of many federal working groups on leveraging data and genomics.